JPWO2020037024A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020037024A5 JPWO2020037024A5 JP2021507775A JP2021507775A JPWO2020037024A5 JP WO2020037024 A5 JPWO2020037024 A5 JP WO2020037024A5 JP 2021507775 A JP2021507775 A JP 2021507775A JP 2021507775 A JP2021507775 A JP 2021507775A JP WO2020037024 A5 JPWO2020037024 A5 JP WO2020037024A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- months
- antibody
- cancer
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 68
- 239000000611 antibody drug conjugate Substances 0.000 claims 16
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 230000002411 adverse Effects 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 229910052697 platinum Inorganic materials 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 206010061818 Disease progression Diseases 0.000 claims 6
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 6
- 230000005750 disease progression Effects 0.000 claims 6
- 108010093470 monomethyl auristatin E Proteins 0.000 claims 6
- 102000002262 Thromboplastin Human genes 0.000 claims 5
- 108010000499 Thromboplastin Proteins 0.000 claims 5
- 108010044540 auristatin Proteins 0.000 claims 5
- 230000004044 response Effects 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 206010061819 Disease recurrence Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 238000009121 systemic therapy Methods 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 201000002628 peritoneum cancer Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000003889 eye drop Substances 0.000 claims 2
- 229940012356 eye drops Drugs 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 108010016626 Dipeptides Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000019025 Hypokalemia Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 206010051792 Infusion related reaction Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 229940125644 antibody drug Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009104 chemotherapy regimen Methods 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000001780 epistaxis Diseases 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000024896 potassium deficiency disease Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229950000154 tisotumab Drugs 0.000 claims 1
- 229950004269 tisotumab vedotin Drugs 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765093P | 2018-08-16 | 2018-08-16 | |
| US62/765,093 | 2018-08-16 | ||
| PCT/US2019/046467 WO2020037024A1 (en) | 2018-08-16 | 2019-08-14 | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534165A JP2021534165A (ja) | 2021-12-09 |
| JPWO2020037024A5 true JPWO2020037024A5 (enExample) | 2022-08-12 |
Family
ID=69525825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507775A Pending JP2021534165A (ja) | 2018-08-16 | 2019-08-14 | 抗組織因子抗体−薬物コンジュゲートおよびがんの治療におけるその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210308208A1 (enExample) |
| EP (1) | EP3836950A4 (enExample) |
| JP (1) | JP2021534165A (enExample) |
| KR (1) | KR20210046016A (enExample) |
| CN (1) | CN112584872A (enExample) |
| AU (1) | AU2019321442A1 (enExample) |
| BR (1) | BR112021001691A2 (enExample) |
| CA (1) | CA3109116A1 (enExample) |
| EA (1) | EA202190102A1 (enExample) |
| IL (1) | IL280617A (enExample) |
| MX (1) | MX2021001058A (enExample) |
| SG (1) | SG11202101428UA (enExample) |
| WO (1) | WO2020037024A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CN112739716B (zh) | 2018-05-07 | 2025-05-27 | 展马博联合股份有限公司 | 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| US20240261424A1 (en) * | 2020-03-30 | 2024-08-08 | National Cancer Center | Antibody drug conjugate |
| EP3919077A1 (en) | 2020-06-04 | 2021-12-08 | BioInvent International AB | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| IL298757A (en) | 2020-06-04 | 2023-02-01 | Bioinvent Int Ab | Improving antibody tolerability associated with intravenous administration |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| RS56599B1 (sr) * | 2010-06-15 | 2018-02-28 | Genmab As | Konjugati humanog antitela sa lekom protiv tkivnog faktora |
| JP6590803B2 (ja) * | 2013-11-21 | 2019-10-16 | ゲンマブ エー／エス | 抗体−薬物コンジュゲート凍結乾燥製剤 |
| KR102419766B1 (ko) * | 2014-05-22 | 2022-07-13 | 비온디스 비.브이. | 항체에 대한 링커 약물의 부위 특이적 접합 및 그 결과로 얻어지는 adc |
| US20190030178A1 (en) * | 2015-09-11 | 2019-01-31 | Genmab A/S | Dosing regimens for anti-tf-antibody drug-conjugates |
| CN111655290A (zh) * | 2017-11-02 | 2020-09-11 | 展马博联合股份有限公司 | 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用 |
| BR112020013679A2 (pt) * | 2018-01-04 | 2020-12-01 | Iconic Therapeutics, Inc. | anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados |
-
2019
- 2019-08-14 MX MX2021001058A patent/MX2021001058A/es unknown
- 2019-08-14 JP JP2021507775A patent/JP2021534165A/ja active Pending
- 2019-08-14 SG SG11202101428UA patent/SG11202101428UA/en unknown
- 2019-08-14 BR BR112021001691-0A patent/BR112021001691A2/pt unknown
- 2019-08-14 CN CN201980054479.8A patent/CN112584872A/zh active Pending
- 2019-08-14 EP EP19849100.3A patent/EP3836950A4/en not_active Withdrawn
- 2019-08-14 EA EA202190102A patent/EA202190102A1/ru unknown
- 2019-08-14 WO PCT/US2019/046467 patent/WO2020037024A1/en not_active Ceased
- 2019-08-14 AU AU2019321442A patent/AU2019321442A1/en active Pending
- 2019-08-14 KR KR1020217007245A patent/KR20210046016A/ko not_active Withdrawn
- 2019-08-14 US US17/268,387 patent/US20210308208A1/en not_active Abandoned
- 2019-08-14 CA CA3109116A patent/CA3109116A1/en active Pending
-
2021
- 2021-02-03 IL IL280617A patent/IL280617A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501776A5 (enExample) | ||
| CN113924318B (zh) | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 | |
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| IL312038A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| JP2022101693A5 (enExample) | ||
| US20240299571A1 (en) | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinations | |
| JP2019031568A5 (enExample) | ||
| JP2020519675A5 (enExample) | ||
| IL278400B2 (en) | Combination of an anti-PD-1 antibody and conjugation of a drug with an anti-TF antibody for use in the treatment of cancer | |
| WO2023240082A2 (en) | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer | |
| JPWO2020037024A5 (enExample) | ||
| JPWO2019173523A5 (enExample) | ||
| JPWO2020092210A5 (enExample) | ||
| JPWO2019183253A5 (enExample) | ||
| JPWO2019217457A5 (enExample) | ||
| JPWO2019217455A5 (enExample) | ||
| KR20250134646A (ko) | 유방암 치료용 항-her2 항체-약물 접합체 | |
| JPWO2021089794A5 (enExample) | ||
| JPWO2021090272A5 (enExample) | ||
| JPWO2021016233A5 (enExample) | ||
| JPWO2022174775A5 (enExample) | ||
| CN121127268A (zh) | 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途 | |
| RU2025111318A (ru) | АНТИ-αvβ6 АНТИТЕЛА И КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| WO2023003790A1 (en) | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents | |
| RU2023128710A (ru) | Антитела против c-met и коньюгаты антитела с лекарственным средством |